Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study

Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study

Hao Dong,1,&ast; Rong Chen,2,&ast; Fang Xu,3,&ast; Fang Cheng4 1Department of Gastroenterology and Hepatology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China; 2Department of Rehabilitation Medicine, the First Affiliated Hospital of S...

Full description

Bibliographic Details
Main Authors:	Dong H, Chen R, Xu F, Cheng F
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-02-01
Series:	Clinical Epidemiology
Subjects:	cholelithiasis lipid-lowering drugs mendelian randomization analysis hmgcr inhibitors pcsk9 inhibitors npc1l1 inhibitors.
Online Access:	https://www.dovepress.com/can-lipid-lowering-drugs-reduce-the-risk-of-cholelithiasis-a-mendelian-peer-reviewed-fulltext-article-CLEP

Similar Items

Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study
by: Shan Luo, et al.
Published: (2023-10-01)

Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study
by: Opeyemi Soremekun, et al.
Published: (2022-04-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting
by: Wenxin Wang, et al.
Published: (2024-01-01)

Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study
by: Heqing Tao, et al.
Published: (2023-06-01)

HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis
by: Zhenyu Zhong, et al.
Published: (2021-10-01)

Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
by: Weijia Xie, et al.
Published: (2023-08-01)

Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study
by: Hangyu Duan, et al.
Published: (2024-03-01)

Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
by: Miles Shen, et al.
Published: (2022-09-01)

The causal effects of thyroid function and lipids on cholelithiasis: A Mendelian randomization analysis
by: Junhong Chen, et al.
Published: (2023-03-01)

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
by: Nikolay Kuzmich, et al.
Published: (2022-01-01)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
by: Nagham N. Hindi, et al.
Published: (2021-08-01)

Mendelian randomization study on the causal relationship between food and cholelithiasis
by: Zhicheng Liu, et al.
Published: (2024-03-01)

Causal association between metabolic syndrome and cholelithiasis: a Mendelian randomization study
by: Qi Zhu, et al.
Published: (2023-06-01)

Blood lipid levels and treatment following an acute coronary syndrome or coronary intervention – Journey from hospital to cardiac rehabilitation
by: David Rott, et al.
Published: (2022-12-01)

Causal associations between human gut microbiota and cholelithiasis: a mendelian randomization study
by: Wei Li, et al.
Published: (2023-05-01)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01)

New Drugs for Treating Dyslipidemia: Beyond Statins
by: Chang Ho Ahn, et al.
Published: (2015-04-01)

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
by: Jia X, et al.
Published: (2022-07-01)

Causal effects from nonalcoholic fatty liver disease on cholelithiasis: A mendelian randomization study
by: Yin‐Shi Su, et al.
Published: (2024-03-01)

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
by: Donatella Zodda, et al.
Published: (2018-01-01)

Associations of lipids and lipid-lowering drugs with risk of stroke: a Mendelian randomization study
by: Hao Qin, et al.
Published: (2023-07-01)

PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
by: Lοukianos S. Rallidis, et al.
Published: (2016-03-01)

Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis
by: Wenrui Ma, et al.
Published: (2021-10-01)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial
by: Lili Lin, et al.
Published: (2023-08-01)

Genetic evidence implicating circulating lipids and lipid drug targets in pterygium
by: Yuchen Cai, et al.
Published: (2023-01-01)

Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study
by: Yinsong Xu, MM, et al.
Published: (2024-04-01)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
by: Alex Smith, et al.
Published: (2021-08-01)

Inclisiran - hope in the fight against dyslipidemia
by: Paulina Krawiec, et al.
Published: (2023-05-01)

Statins as a risk factor for diabetic retinopathy: a Mendelian randomization and cross-sectional observational study
by: Chengming Chen, et al.
Published: (2024-03-01)

Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
by: Keshav Kumar Gupta, et al.
Published: (2018-12-01)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
by: Tina Levstek, et al.
Published: (2023-03-01)

Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study
by: Wuqing Huang, et al.
Published: (2021-12-01)

PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study
by: Kai Zhang, et al.
Published: (2024-05-01)

Targeted Strategy in Lipid-Lowering Therapy
by: Ezgi Dayar, et al.
Published: (2022-05-01)

Is lower better? Is lowest the best?
by: Lale Tokgözoğlu
Published: (2017-04-01)

Causal association between serum total bilirubin and cholelithiasis: a bidirectional two-sample Mendelian randomization study
by: Yang Sun, et al.
Published: (2023-07-01)

Plasma campesterol and ABCG5/ABCG8 gene loci on the risk of cholelithiasis and cholecystitis: evidence from Mendelian randomization and colocalization analyses
by: Jiarui Mi, et al.
Published: (2024-02-01)

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified
by: Baum SJ, et al.
Published: (2019-11-01)